NHS England Funds 'Life-Changing' Treatment for Periodic Fever Syndromes

Pavankumar Kamat

March 04, 2020

NHS England is funding a 'life-changing treatment' for certain individuals with periodic fever syndromes (PFS), a group of rare conditions characterised by fever, joint pains and swelling. Patients with PFS often experience inflammatory 'flares' involving chest or joint pains, headaches, mouth ulcers and skin rash.

Coinciding with World Rare Diseases Day on 29th February 2020, the NHS announced a deal with Novartis for using the immunomodulatory drug canakinumab (Ilaris) to reduce the frequency of flares in children and adults with PFS.

An estimated 168 individuals in England have PFS. Around 80% of them would be eligible to receive canakinumab, including patients with familial Mediterranean fever, mevalonate kinase deficiency (hyperimmunoglobulinaemia D syndrome) and tumour necrosis factor receptor-associated periodic syndrome.

Current treatments for PFS include anti-inflammatory and immune-suppressing drugs which are not always effective and some are associated with unfavourable side effects such as weight gain, thinning of skin and bone and increased risk for diabetes and infections.

In a news release, Sir Simon Stevens, chief executive of NHS England, said: "Some illnesses affect a small number in a big way, which is why the NHS is increasingly bringing innovative, specialised and targeted treatments to people who need them."

Adapted from Univadis from Medscape.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: